- Home
- AUDC vs ENGN Comparison
AUDC vs ENGN Comparison
Compare AUDC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- ENGN
- Stock Information
- Founded
- AUDC 1992
- ENGN 1999
- Country
- AUDC Israel
- ENGN Canada
- Employees
- AUDC N/A
- ENGN N/A
- Industry
- AUDC Telecommunications Equipment
- ENGN
- Sector
- AUDC Utilities
- ENGN
- Exchange
- AUDC Nasdaq
- ENGN Nasdaq
- Market Cap
- AUDC 299.7M
- ENGN 297.7M
- IPO Year
- AUDC 1999
- ENGN N/A
- Fundamental
- Price
- AUDC $9.60
- ENGN $4.44
- Analyst Decision
- AUDC Buy
- ENGN Buy
- Analyst Count
- AUDC 2
- ENGN 9
- Target Price
- AUDC $11.25
- ENGN $25.22
- AVG Volume (30 Days)
- AUDC 72.6K
- ENGN 27.4K
- Earning Date
- AUDC 05-06-2025
- ENGN 03-10-2025
- Dividend Yield
- AUDC 1.91%
- ENGN N/A
- EPS Growth
- AUDC 78.82
- ENGN N/A
- EPS
- AUDC 0.50
- ENGN N/A
- Revenue
- AUDC $242,176,000.00
- ENGN N/A
- Revenue This Year
- AUDC $5.11
- ENGN N/A
- Revenue Next Year
- AUDC $3.81
- ENGN N/A
- P/E Ratio
- AUDC $18.90
- ENGN N/A
- Revenue Growth
- AUDC N/A
- ENGN N/A
- 52 Week Low
- AUDC $7.70
- ENGN $4.00
- 52 Week High
- AUDC $12.76
- ENGN $17.10
- Technical
- Relative Strength Index (RSI)
- AUDC 34.16
- ENGN 36.32
- Support Level
- AUDC $9.24
- ENGN $4.00
- Resistance Level
- AUDC $10.13
- ENGN $5.00
- Average True Range (ATR)
- AUDC 0.28
- ENGN 0.46
- MACD
- AUDC -0.04
- ENGN -0.03
- Stochastic Oscillator
- AUDC 24.83
- ENGN 27.50
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.